Guidant reintroduces defibrillator line

Guidant is making its return to the market for defibrillators for patients with congestive heart failure. On Friday, the Indianapolis-based company won FDA approval for a fix for a defect which caused a small number of units to malfunction. The highly expensive devices, which cost around $30,000 each, were pulled from the market in June. Guidant shares rose in response to the news this morning, climbing 4 percent to $71.62 in morning trading.

- see this story from TheStreet.com

PLUS: The New York Times this weekend published another account of a serious defibrillator incident. Story